The latest situation of vaccination in Covid-19!

The State Council Joint Prevention and Control Mechanism held a press conference on the afternoon of March 15th to introduce the situation of promoting vaccination in COVID-19. Let’s pay attention together!

About vaccination

By March 14th, 64.98 million people had been vaccinated with Covid-19 vaccine.

At present, all localities are promoting vaccination safely, orderly and vigorously. As of March 14th, 64.98 million people have been vaccinated with Covid-19 vaccine. At present, vaccination is being organized and implemented according to the principle that key groups, high-risk groups and other groups are promoted in order, and the coverage rate of vaccine population in Covid-19 is steadily improved.

If you miss the centralized inoculation, you can replant at the local inoculation unit nearby.

At present, most of the vaccinated people in various places involve key industries and places, mainly relying on their units to organize centralized vaccination, and some temporary vaccination points have been added in places where the target population is concentrated. If individual target population fails to participate in centralized vaccination due to personal reasons, they can also replant at the nearest inoculation unit, but they should contact the inoculation unit in advance or make an appointment in advance according to the requirements of the local health administrative department, disease control institution or inoculation unit. If you have questions about vaccination in Covid-19, you can ask the local health administrative departments, disease control institutions and vaccination units through online or telephone consultation.

Vaccination of high-risk groups such as the elderly and patients with basic diseases should be arranged according to the progress of vaccine research and development.

The vaccination of high-risk groups mainly includes the elderly and patients with basic diseases. At present, the data of clinical trials on the protection effectiveness of this group of people are not enough, so the vaccination work of this group of people needs to be arranged according to the progress of vaccine research and development. After the clinical trials have obtained sufficient data on safety and effectiveness, large-scale vaccination of relevant people will be carried out in time.

COVID-19 vaccine is usually separated from other vaccinations for at least two weeks.

Usually, the interval between COVID-19 vaccine and other vaccinations should be at least two weeks, but in some special cases, such as animal bites or trauma, rabies vaccine or tetanus toxoid should be vaccinated at this time. In this case, it is not recommended to vaccinate at the interval of two weeks, and rabies vaccine or tetanus vaccine can be given priority regardless of the interval.

It is recommended to seek medical advice in time when you encounter suspected adverse reaction symptoms after vaccination.

Vaccine is a foreign antigen to human body. There will be some adverse reactions after vaccination, but most of them are general reactions, which means that these reactions can heal themselves without treatment, but sometimes they will encounter suspected adverse reactions after vaccination, and the symptoms may be slightly worse. At this time, it is recommended that the recipients seek medical treatment in time. In this process, if the clinician suspects that it is caused by the vaccine, he will report it, and then he will do relevant investigation and diagnosis.

The best way to prevent COVID-19 is to vaccinate.

From the analysis of infection risk, although the epidemic situation in China is generally stable, there are still risks of epidemic import and local epidemic. For the vast majority of people, if there is no immunity against Covid-19, they may get sick, and some people may be more serious after getting sick. Therefore, the best way to prevent COVID-19 is to vaccinate. Vaccination can effectively protect individuals and people, and vaccination can reduce infection rate, severe illness rate and death rate.

About vaccine research and development and circulation

At present, 17 COVID-19 vaccines have entered the clinical stage in China, and 4 vaccines have been conditionally approved.

At present, 17 COVID-19 vaccines have entered the clinical stage in our country, four of them have been approved with conditions, and the other three technical routes are basically in the third phase of clinical practice or will enter the third phase of clinical practice immediately. Clinical trials need to obtain sufficient clinical research data. Once sufficient data is obtained to prove that it meets the efficacy of the scheme design and has acceptable safety data, the applicant can apply to National Medical Products Administration for listing, and National Medical Products Administration will organize the review at the first time to ensure the safe and effective vaccine to be listed as soon as possible.

The four Covid-19 vaccines are divided into two technical routes.

There are three inactivated vaccines, one is adenovirus vector vaccine. Inactivated vaccine is actually a vaccine prepared by a series of purification techniques after the live virus is inactivated by physical and chemical methods. Its main feature is that the composition of the vaccine is similar to that of the natural virus, which is the closest. Usually, the immune response is also strong and has good safety. Its vaccine is relatively stable, it can be stored for two to three years at 2-8 degrees for a long time, and it is convenient to transport and use in remote places. It is immunized with two needles. Adenovirus vector vaccine, China adopts adenovirus type 5 as the vector, introduces Covid-19 antigen gene, and makes live vector vaccine through bioreactor. The preparation process is relatively simple, and the cost is relatively low, because it is mainly developed on the basis of the original platform of Ebola vaccine of adenovirus type 5 in our country. This vaccine can not only induce the production of good neutralizing antibodies, but also has a feature of enhancing cellular immunity. The adopted immunization program is one-shot immunization. One-shot immunization is really convenient for some special emergency groups.

The whole process of vaccine control can be traced back to the source and the destination.

In terms of tracking the flow direction, the state has established a national electronic traceability collaborative platform for vaccines, and all localities report the required information to the platform in a timely and accurate manner, so that the vaccine can be traced throughout the process, and the source and destination of the vaccine can be traced. In terms of the safety management of vaccine circulation and use, CDC and vaccination units strictly control the entry and exit of vaccines, and regularly monitor and record the temperature of vaccines in Covid-19 during storage and transportation to ensure the safety of storage and transportation.

Influence of Covid-19 Mutant on Vaccine

At present, it is not found that Covid-19 mutant significantly affects the protection rate of COVID-19 vaccine listed in China.

At present, it has not been found that the mutant strain from Covid-19 has a significant impact on the protection rate of COVID-19 vaccine conditionally listed in China. R&D enterprises all use vaccine immune serum to test and evaluate the cross neutralization ability of several mutant strains collected at present, and the latest report has not found that the neutralization activity of inactivated vaccine and recombinant protein vaccine on mutant strains, including South African strains, has obviously decreased, so it is necessary to follow up and study.

Take measures to deal with the influence caused by virus mutation

In order to effectively deal with the impact of virus mutation, on the one hand, we should closely monitor and monitor in real time, collect it as soon as possible after discovery, and then measure it after collection, so as to find out the impact of Covid-19 mutant on the vaccine in time. On the other hand, strengthening the platform construction of vaccine research and development, through the deployment of five technical routes, China has established a very strong vaccine research and development platform. At the same time, we will actively study a new generation of vaccines, and once the immune effect of vaccines disappears or is greatly reduced due to virus mutation, we can develop vaccines for mutant strains in the shortest time.

remind

Ministry of Culture and Tourism: The proportion of receptionists such as entertainment places in areas with low epidemic risk is no longer subject to uniform restrictions.

Recently, the Ministry of Culture, Tourism and Tourism issued the Notice on Further Strengthening the Prevention and Control of Normalized Epidemic Situation in Performance Places, Internet Service Places and Entertainment Places such as theaters. In areas with low risk of epidemic situation, the proportion of consumers in performance places, Internet Service Places and Entertainment Places such as theaters is no longer subject to uniform restrictions, and the party committees and governments of all provinces (autonomous regions and municipalities) will take control according to the local epidemic prevention and control situation. To hold large-scale commercial performances, it is necessary to strengthen communication and coordination with public security departments, and appropriately control the number of people according to local epidemic prevention and control requirements.

Read in detail: Notice on further strengthening the prevention and control of normalized epidemic situation in theaters and other performance venues, Internet service places and entertainment places.